How a new generation of FDA reviewers can meet the future demands of cell and gene therapy

Regulatory agencies around the world are currently dealing with the departure of long-term staff members who have witnessed the evolution of the cell and gene therapy field over decades. However, there are also benefits to a fresh approach. David McCall, Senior Editor, BioInsights, speaks with former Senior Investigator at the US FDA, Deborah Hursh, about what recent reorganization at the FDA means for new agency staffers and sponsors alike.

Please enter your email to access content Read now